HPV Screening with Self-Collection Endorsed by Two Major U.S. Health Organizations
In late 2025, the American Cancer Society (ACS) released updated cervical cancer screening guidelines that recommend human papillomavirus (HPV) testing as the primary screening method for most adults with a cervix. Shortly thereafter, in January 2026, the Health Resources and Services Administration (HRSA), an agency within the U.S. Department of Health and Human Services, endorsed its own set of cervical cancer screening guidelines. Both organizations now affirm that self-collected HPV samples are an acceptable alternative to clinician-collected specimens, marking a significant step toward expanding access to cervical cancer screening.
The alignment between ACS and HRSA on the acceptability of self-sampling reflects growing evidence that self-collected HPV tests are accurate and acceptable to patients, particularly in underserved or hard-to-reach populations. This development could help reduce barriers related to geographic access, discomfort with pelvic exams, or lack of regular gynecological care. According to the World Health Organization, self-sampling for HPV has been shown to increase screening participation in multiple countries, supporting its inclusion in national guidelines.
Both guidelines agree that HPV primary testing is preferred over co-testing (HPV test plus Pap smear) or Pap testing alone for individuals aged 30 to 65 at average risk. If HPV primary testing is unavailable, co-testing is recommended, followed by Pap testing alone as a last resort. For those who receive normal results from HPV primary testing or co-testing using a clinician-collected sample, rescreening is advised every five years. However, the ACS specifies that individuals who self-collect their HPV sample and receive normal results should be rescreened every three years—a distinction not included in the HRSA guidelines.
Where the ACS and HRSA Guidelines Align on HPV Screening
The consensus between the two agencies covers several key aspects of cervical cancer screening. Both recommend initiating screening no later than age 30 for average-risk individuals, with HPV primary testing as the preferred method. This test detects high-risk HPV strains responsible for approximately 70% of cervical cancers, according to the National Cancer Institute. When HPV testing is not available, both organizations support co-testing or Pap testing alone as acceptable alternatives.
Self-collection is explicitly endorsed by both ACS and HRSA as a valid option when clinic-based collection is not feasible. The ACS notes that while provider-collected samples are preferred, self-sampling can help overcome barriers such as limited access to gynecologists, prior trauma, or cultural discomfort with pelvic exams. HRSA similarly states that self-collected HPV tests are acceptable for screening, particularly in community health centers, mobile clinics, or other non-traditional settings.
Regarding screening intervals, both agree that individuals with a history of normal Pap tests should be rescreened every three years. For those with normal results from HPV primary testing or co-testing using clinician-collected samples, the interval extends to five years. Screening can generally cease at age 65 if prior results have been consistently normal, although the ACS provides more specific criteria, requiring a decade of negative results—such as two negative HPV tests at ages 60 and 65, or three consecutive negative Pap tests with the most recent at age 65.
Where the Guidelines Differ: Starting Age and Screening Frequency
The primary divergence between the ACS and HRSA guidelines lies in the recommended starting age for cervical cancer screening. The ACS advises beginning screening at age 25, regardless of the test used, citing the rarity of cervical cancer in individuals under 25 and the potential harms of over-screening, such as unnecessary follow-up procedures. In contrast, HRSA recommends initiating screening at age 21 with Pap tests every three years until age 29, after which HPV primary testing or co-testing should start.
This difference reflects varying interpretations of risk-benefit analysis in younger populations. While cervical cancer is extremely rare under age 25, precancerous lesions can occur, and early detection may benefit some individuals. However, the ACS emphasizes that most abnormalities in younger people resolve spontaneously, and aggressive screening can lead to overtreatment. HRSA’s approach aligns with longstanding U.S. Preventive care norms, though it has been criticized by some experts for potentially increasing low-yield screening in adolescents and young adults.
Another distinction involves follow-up intervals after self-collected HPV testing. The ACS recommends rescreening in three years for individuals who self-collect and test negative, arguing that self-sampling may have slightly different performance characteristics in real-world settings. HRSA does not currently differentiate based on collection method in its guidelines, maintaining a five-year interval for all negative HPV primary tests regardless of who collected the sample.
What Self-Collected HPV Testing Means for Patients and Providers
The endorsement of self-collection by two major U.S. Health organizations could significantly expand access to cervical cancer screening, particularly in rural areas, underserved communities, and among individuals who avoid clinical settings due to stigma, disability, or past negative experiences. Self-collection kits typically involve a simple vaginal swab that patients can perform themselves in a clinic, pharmacy, mobile van, or even at home, depending on local regulations and program design.
Studies have shown that self-collected HPV samples are highly accurate when processed in certified laboratories, with sensitivity and specificity comparable to clinician-collected specimens. The U.S. Food and Drug Administration has cleared several HPV tests for use with self-collected samples, including those used in pilot programs by the Centers for Disease Control and Prevention and the National Cancer Institute.
For healthcare providers, offering self-collection may reduce the burden of conducting pelvic exams while maintaining screening quality. It also allows integration into primary care, urgent care, and pharmacy-based settings, potentially increasing screening rates among those who do not regularly visit gynecologists. HRSA’s guidelines carry particular weight in shaping insurance coverage, as federal regulations require most private health plans to cover preventive services recommended by HRSA without cost-sharing, a rule expected to seize effect in 2027.
Despite these advances, experts stress that self-collection is not a replacement for follow-up care. Individuals who test positive for high-risk HPV will still need diagnostic evaluation, which may include colposcopy and biopsy. Public health officials emphasize that the goal is not merely to increase screening rates but to ensure timely follow-up and treatment when abnormalities are detected.
Broader Implications for Cervical Cancer Prevention
The endorsement of self-sampling aligns with global efforts to eliminate cervical cancer as a public health problem. The World Health Organization’s global strategy calls for 90% of girls to be vaccinated against HPV, 70% of women to be screened with a high-performance test by age 35 and again by age 45, and 90% of women with precancer or cancer to receive treatment. Self-collection is seen as a key tool to reach the screening target, especially in low- and middle-income countries where pelvic exams are scarce.
In the United States, cervical cancer incidence and mortality have declined significantly over the past decades due to widespread Pap testing and, more recently, HPV vaccination. However, disparities persist, with higher rates of cervical cancer among Black, Hispanic, Indigenous, and low-income women, often linked to unequal access to screening and follow-up care. Expanding access through self-collection could help narrow these gaps.
Ongoing research is evaluating the effectiveness of self-sampling in real-world programs, including optimal distribution methods, patient education strategies, and integration with electronic health records for result tracking and recall. The National Institutes of Health and the Agency for Healthcare Research and Quality are supporting studies to assess long-term outcomes and cost-effectiveness of self-sampling programs across diverse U.S. Populations.
Next Steps and Where to Identify Official Guidance
Individuals interested in cervical cancer screening should consult their healthcare provider to determine the most appropriate test based on age, risk factors, and local availability. Official guidelines from the American Cancer Society are available on its website, as are HRSA’s preventive services recommendations through the U.S. Department of Health and Human Services. The Centers for Disease Control and Prevention also provides up-to-date information on HPV prevention, screening, and vaccination.
As implementation of these guidelines progresses, particularly with insurance coverage changes expected in 2027, stakeholders including patient advocacy groups, health plans, and public health agencies will monitor impacts on screening rates, equity of access, and cervical cancer incidence. The next major update to national screening guidelines is anticipated from the U.S. Preventive Services Task Force, whose recommendations are currently under review and expected to be released in the coming years.
For those seeking to learn more about HPV, cervical cancer prevention, or self-sampling options, reputable sources include the National Cancer Institute, the World Health Organization’s cervical cancer elimination initiative, and peer-reviewed journals such as The Lancet Oncology and Journal of the National Cancer Institute. Staying informed through credible channels ensures that decisions about screening are based on the best available evidence.